Ibex Investors’s AtriCure ATRC Stock Holding History

Ibex Investors’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,825	Closed	-$204K	–	165
2018 Q3	$204K	Buy	+5,825	New	+$184K	0.11%	157

Other funds holding ATRC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ibex Investors's ATRC Position: Q4 2018 in Review

Ibex Investors sold out of AtriCure (ATRC) in Q4 2018, closing a stake of 5,825 shares — an estimated $204K sold.

Ibex Investors first reported a position in ATRC in Q3 2018 and held it in 1 quarter. The position peaked at $204K in Q3 2018. 147 funds tracked by Wall St. Rank hold ATRC as of Q4 2018.

Ibex Investors reported no remaining AtriCure position as of Q4 2018 after selling out during the quarter.
Ibex Investors sold 5,825 AtriCure shares in Q4 2018, an estimated $204K.
Ibex Investors first reported a position in AtriCure in Q3 2018 and held it in 1 quarter.
Ibex Investors's AtriCure position peaked at $204K in Q3 2018.
147 funds tracked by Wall St. Rank held AtriCure as of Q4 2018.

Based on Ibex Investors's 13F filing for Q4 2018, filed 13 Feb 2019.